HK Stock Movement | PEGBIO CO-B (02565) Rises Over 5% as PB-119 Approval Accelerates Global Commercialization Strategy

Stock News11-18

PEGBIO CO-B (02565) surged more than 5%, reaching HK$63.8 by the time of writing, with a trading volume of HK$29.26 million. The company recently announced that China's National Medical Products Administration (NMPA) has approved the new drug application for its core product, PB-119.

PB-119, branded as Paitakang®, is a next-generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by the company, requiring only once-weekly administration. The product has been recognized as a national Class 1 innovative drug under China's "Major New Drug Innovation" initiative.

In October, PEGBIO CO-B entered a strategic partnership with UAE-based pharmaceutical research leader PDC FZ-LLC ("PDC"), granting exclusive rights for the development, distribution, marketing, and commercialization of its core product, Visepegenatide (PB-119), in the Middle East and Africa. This collaboration marks a critical milestone in the company's global commercialization strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167142529?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 13:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167142529","market":"other","top_or_hot":-1,"title":"HK Stock Movement | PEGBIO CO-B (02565) Rises Over 5% as PB-119 Approval Accelerates Global Commercialization Strategy","media":"Stock News","content":"<p>PEGBIO CO-B (02565) surged more than 5%, reaching HK$63.8 by the time of writing, with a trading volume of HK$29.26 million. The company recently announced that China's National Medical Products Administration (NMPA) has approved the new drug application for its core product, PB-119.</p>\n<p>PB-119, branded as Paitakang®, is a next-generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by the company, requiring only once-weekly administration. The product has been recognized as a national Class 1 innovative drug under China's \"Major New Drug Innovation\" initiative.</p>\n<p>In October, PEGBIO CO-B entered a strategic partnership with UAE-based pharmaceutical research leader PDC FZ-LLC (\"PDC\"), granting exclusive rights for the development, distribution, marketing, and commercialization of its core product, Visepegenatide (PB-119), in the Middle East and Africa. This collaboration marks a critical milestone in the company's global commercialization strategy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | PEGBIO CO-B (02565) Rises Over 5% as PB-119 Approval Accelerates Global Commercialization Strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | PEGBIO CO-B (02565) Rises Over 5% as PB-119 Approval Accelerates Global Commercialization Strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-18 13:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PEGBIO CO-B (02565) surged more than 5%, reaching HK$63.8 by the time of writing, with a trading volume of HK$29.26 million. The company recently announced that China's National Medical Products Administration (NMPA) has approved the new drug application for its core product, PB-119.</p>\n<p>PB-119, branded as Paitakang®, is a next-generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by the company, requiring only once-weekly administration. The product has been recognized as a national Class 1 innovative drug under China's \"Major New Drug Innovation\" initiative.</p>\n<p>In October, PEGBIO CO-B entered a strategic partnership with UAE-based pharmaceutical research leader PDC FZ-LLC (\"PDC\"), granting exclusive rights for the development, distribution, marketing, and commercialization of its core product, Visepegenatide (PB-119), in the Middle East and Africa. This collaboration marks a critical milestone in the company's global commercialization strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161726","symbol_name":"生物医药","start_time":0,"source_url":"","article_id":"1167142529","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167142529","pubTimestamp":1763444654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"PEGBIO CO-B (02565) surged more than 5%, reaching HK$63.8 by the time of writing, with a trading volume of HK$29.26 million. The company recently announced that China's National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161726":"生物医药","399441":"生物医药","BK4211":"区域性银行","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","PB":"Prosperity Bancshares Inc","BK1161":"生物科技","02565":"派格生物医药-B","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC"},"translate_title":"港股动向|PB-119获批加速全球商业化策略，培格生物CO-B(02565)涨超5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1,"399441":1,"PB":1,"02565":1},"content_text":"PEGBIO CO-B (02565) surged more than 5%, reaching HK$63.8 by the time of writing, with a trading volume of HK$29.26 million. The company recently announced that China's National Medical Products Administration (NMPA) has approved the new drug application for its core product, PB-119.\nPB-119, branded as Paitakang®, is a next-generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by the company, requiring only once-weekly administration. The product has been recognized as a national Class 1 innovative drug under China's \"Major New Drug Innovation\" initiative.\nIn October, PEGBIO CO-B entered a strategic partnership with UAE-based pharmaceutical research leader PDC FZ-LLC (\"PDC\"), granting exclusive rights for the development, distribution, marketing, and commercialization of its core product, Visepegenatide (PB-119), in the Middle East and Africa. This collaboration marks a critical milestone in the company's global commercialization strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167142529","isCrawlerRequest":true}